Farmatika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 299,870 | 358,731 | 483,647 | 693,725 | 637,207 | 573,623 | 555,057 | 447,919 |
| Profit before tax | 69,352 | 55,199 | 49,930 | 70,094 | 66,118 | 48,860 | 47,180 | 39,570 |
| Net profit | 65,874 | 46,621 | 42,353 | 58,180 | 56,191 | 41,501 | 40,090 | 33,233 |
| Equity | 74,260 | 81,881 | 100,196 | 145,376 | 173,370 | 198,871 | 217,961 | 224,694 |
| Liabilities | 47,206 | 51,772 | 66,787 | 59,455 | 69,504 | 50,733 | 73,105 | 52,472 |
| Non-current assets | 24,727 | 20,608 | 16,195 | 11,782 | 7,369 | 40,956 | 90,205 | 89,832 |
| Current assets | 96,707 | 112,864 | 150,536 | 192,799 | 235,074 | 208,198 | 200,507 | 186,906 |
| Total assets | 121,434 | 133,472 | 166,731 | 204,581 | 242,443 | 249,154 | 290,712 | 276,738 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 97,507 | 94,331 | 73,482 |
| Social insurance contributions | - | - | - | - | - | 1,011 | 981 | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | +111.8% | +19.6% | +34.8% | +43.4% | -8.1% | -10.0% | -3.2% | -19.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 54.2% | 34.9% | 25.4% | 28.4% | 23.2% | 16.7% | 13.8% | 12.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 88.7% | 56.9% | 42.3% | 40.0% | 32.4% | 20.9% | 18.4% | 14.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 22.0% | 13.0% | 8.8% | 8.4% | 8.8% | 7.2% | 7.2% | 7.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 23.1% | 15.4% | 10.3% | 10.1% | 10.4% | 8.5% | 8.5% | 8.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.6 | 0.6 | 0.7 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 143,940 | 179,366 | 232,154 | 260,144 | 212,402 | 191,208 | 222,023 | 223,960 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Farmatika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-04-20 | 2026-04-22 | 335.35 |
Farmatika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Farmatika, UAB (code 303089950) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €447.9K and net profit of €33.2K, with a profit margin of 7.4%. Revenue declined by 19.3% year on year and was 21.9% lower than two years earlier, showing a moderate downward trend across 2023–2025. Despite the lower turnover, profitability remained positive and relatively stable, with net profit moving from €41.5K in 2023 to €40.1K in 2024 and €33.2K in 2025. The balance sheet remained solid in 2025, with total assets of €276.7K, equity of €224.7K and liabilities of €52.5K. Equity represented 81.2% of assets, while debt-to-equity stood at 0.23, indicating a conservative capital structure. Asset turnover was 1.62x, ROE was 14.8%, and ROA was 12.0%. Revenue per employee was €224.0K and profit per employee was €16.6K, suggesting efficient productivity relative to turnover.